Statistiche di base
| LEI | 529900YTTXUSFQTAKY40 |
| CIK | 1340652 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ChemoCentryx Inc
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| October 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-35420 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its c |
|
| October 20, 2022 |
As filed with the Securities and Exchange Commission on October 20, 2022 POSASR As filed with the Securities and Exchange Commission on October 20, 2022 Registration No. |
|
| October 20, 2022 |
As filed with the Securities and Exchange Commission on October 20, 2022 As filed with the Securities and Exchange Commission on October 20, 2022 Registration No. |
|
| October 20, 2022 |
Amended and Restated Bylaws of ChemoCentryx, Inc. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF CHEMOCENTRYX, INC. ARTICLE I Stockholders Section 1.1. Annual Meetings. An annual meeting of stockholders of ChemoCentryx, Inc. (the ?Corporation?) for the election of directors and for the transaction of any other proper business shall be held at such date, time and place (either within or without the State of Delaware) or may not be held at any place, b |
|
| October 20, 2022 |
As filed with the Securities and Exchange Commission on October 20, 2022 S-8 POS As filed with the Securities and Exchange Commission on October 20, 2022 Registration No. |
|
| October 20, 2022 |
Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX TAVNEOS? (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., (Oct. 20, 2022) ? Amgen (NASDAQ: AMGN) today announced that it has |
|
| October 20, 2022 |
Amended and Restated Certificate of Incorporation of ChemoCentryx, Inc. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CHEMOCENTRYX, INC. 1. The name of the Corporation is ChemoCentryx, Inc. (the ?Corporation?). 2. The Registered Office of the Corporation in the State of Delaware is located at 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808. The name of its registered agent at such address is Corporation Service Company. 3. The |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 18, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 18, 2022 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation or organization) |
|
| October 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| September 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission F |
|
| September 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission F |
|
| September 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| August 31, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| August 31, 2022 |
Filed by ChemoCentryx, Inc. pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: ChemoCentryx, Inc. Commission File No. of Subject Company: 001-35420 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the R |
|
| August 31, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) ChemoCentryx, Inc. |
|
| August 23, 2022 |
Table of Contents Filed by ChemoCentryx, Inc. pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: ChemoCentryx, Inc. Commission File No. of Subject Company: 001-35420 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1 |
|
| August 9, 2022 |
Filed by ChemoCentryx, Inc. pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: ChemoCentryx, Inc. Commission File No. of Subject Company: 001-35420 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the R |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35420 ChemoCentryx, Inc. |
|
| August 8, 2022 |
Filed by ChemoCentryx, Inc. pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: ChemoCentryx, Inc. Commission File No. of Subject Company: 001-35420 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the R |
|
| August 4, 2022 |
EX-99.1 Exhibit 99.1 News Release AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH Acquisition Includes TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease Tavneos Adds to Amgen’s Decades-Long Leadership in Inflammation and Nephrology THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 – Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File |
|
| August 4, 2022 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER dated as of August 3, 2022 among CHEMOCENTRYX, INC., AMGEN INC. and CARNATION MERGER SUB, INC. TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. Other Definitional and Interpretative Provisions 11 ARTICLE 2 THE MERGER Section 2.01. The Merger 12 Section 2.02. Conversion of Shares 13 Section 2.03. Surren |
|
| July 5, 2022 |
Exhibit 99.1 ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director ? Ms. Herron brings more than 25 years of therapeutics commercial experience and brand management to ChemoCentryx Board ? SAN CARLOS, Calif., July 5, 2022 ? ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effe |
|
| July 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2022 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2022 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 1, 2022 |
Exhibit 99.1 ChemoCentryx Announces Changes to its Board of Directors ? David E. Wheadon, M.D., Elected to the Board as an Independent Director ? ? Henry A. McKinnell, Jr., to Retire from Board ? SAN CARLOS, Calif., May 31, 2022 ? ChemoCentryx, Inc., (Nasdaq: CCXI), today announced changes to the composition of its Board of Directors. David E. Wheadon, M.D., has been elected to the Board as an ind |
|
| May 10, 2022 |
Amended and Restated Non-Employee Director Compensation Policy. CHEMOCENTRYX, INC. Non-Employee DIRECTOR COMPENSATION POLICY (As Amended and Restated Effective February 22, 2022) Non-employee members of the board of directors (the ?Board?) of ChemoCentryx, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Policy (this ?Policy?). The cash and equity compensation described in th |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35420 ChemoCentryx, Inc. |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 5, 2022 |
Exhibit 99.1 ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights — Five-fold increase in net sales of TAVNEOS® (avacopan) quarter-over-quarter with $5.4 million in Q1 2022 — — Marked growth in key performance indicators (Q1 2022 to Q4 2021 comparison): - 195% TAVNEOS new Patient Start Forms - 275% Unique Prescribers - 308% Patients on Drug — — Global expansion continues |
|
| May 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 5, 2022 |
DEF 14A 1 d294455ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Us |
|
| March 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-35420 ChemoCentryx, I |
|
| March 1, 2022 |
Second Amendment to Amended and Restated Loan and Security Agreement Exhibit 10.43 SECOND AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of December 15, 2021 (the ?Second Amendment Effective Date?), is entered into by and between CHEMOCENTRYX, INC., a Delaware corporation, and each of its Qualified Subsidiaries (hereinafter collectively referred to |
|
| March 1, 2022 |
Exhibit 99.1 ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights ? Total revenue of $32.2 million in 2021 with $2.3 million in Q4; TAVNEOS? (avacopan) US net product sales of approximately $1.0 million in Q4 2021 following US Food and Drug Administration (FDA) approval in ANCA-associated vasculitis ? ? TAVNEOS also approved in European Union (EU) triggeri |
|
| March 1, 2022 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a list of subsidiaries of the Registrant as of December 31, 2021. Company Jurisdiction of Incorporation ChemoCentryx Limited United Kingdom ChemoCentryx Ireland Limited Ireland |
|
| March 1, 2022 |
Employment Agreement, effective as of October 5, 2021, by and between the Registrant and Rita Jain. Exhibit 10.16 October 5, 2021 Rita I. Jain, M.D. Dear Rita: On behalf of ChemoCentryx, Inc. (?ChemoCentryx? or the ?Company?), I am pleased to offer you employment as Executive Vice President, Chief Medical Officer. In this position, you will report to Thomas Schall, President and Chief Executive Officer, and will work from your Chicago, Illinois location while travelling regularly to ChemoCentryx |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 14, 2022 |
CCXI / ChemoCentryx Inc / RA CAPITAL MANAGEMENT, L.P. - CHEMOCENTRYX, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ChemoCentryx, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 16383L106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 14, 2022 |
CCXI / ChemoCentryx Inc / Schall Thomas J. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 10) ChemoCentryx, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 16383L106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rul |
|
| February 9, 2022 |
CCXI / ChemoCentryx Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: ChemoCentryx Inc. Title of Class of Securities: Common Stock CUSIP Number: 16383L106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??R |
|
| November 12, 2021 |
Exhibit 99.1 Positive Recommendation for Use of TAVNEOS? (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) SAN CARLOS, Calif., November 12, 2021 ? ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the European Medicines Agency?s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion |
|
| November 12, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 9, 2021 |
Exhibit 99.1 ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights ? U.S. Food & Drug Administration (FDA) approves TAVNEOSTM (avacopan) in ANCA-Associated Vasculitis in October ? ? TAVNEOS now launched in the U.S. ? ? TAVNEOS approved also in Japan; European CHMP opinion expected this month ? ? Pipeline advances: Company intends to meet with FDA on path for TAVNEOS in C3 |
|
| November 9, 2021 |
First Amendment to Amended and Restated Loan and Security Agreement Exhibit 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of July 23, 2021 (the ?First Amendment Effective Date?), is entered into by and between CHEMOCENTRYX, INC., a Delaware corporation, and each of its Qualified Subsidiaries (hereinafter collectively referred to as the ? |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35420 ChemoCentryx, Inc. |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 14, 2021 |
CCXI / ChemoCentryx Inc / Vifor (International) Ltd - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* ChemoCentryx, Inc. (Name of Issuer) Common Stock, par value $0.001 Per Share (Title of Class of Securities) 16383L106 (CUSIP Number) Dr. Oliver P. Kronenberg Group General Counsel Vifor Pharma Management Ltd. Flughofstrasse 61, CH-8152, Glattbrugg, Switzerlan |
|
| October 13, 2021 |
144 1 d141359d144.htm 144 OMB APPROVAL OMB Number: 3235-0101 Expire: June 30, 2020 Estimated average burden hours per response 1.00 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 SEC USE ONLY DOCUMENT SEQUENCE NO. CUSIP NUMBER WORK LOCATION ATTENTION: Transmit for filing 3 |
|
| October 12, 2021 |
Offer Letter between the Company and Rita I. Jain, dated October 5, 2021 Exhibit 10.1 October 5, 2021 Rita I. Jain, M.D. Dear Rita: On behalf of ChemoCentryx, Inc. (?ChemoCentryx? or the ?Company?), I am pleased to offer you employment as Executive Vice President, Chief Medical Officer. In this position, you will report to Thomas Schall, President and Chief Executive Officer, and will work from your Chicago, Illinois location while travelling regularly to ChemoCentryx |
|
| October 12, 2021 |
Exhibit 99.1 ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product SAN CARLOS, Calif., October 11, 2021 ? ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Rita I. Jain, M.D., as Executive Vice President, Chief Medical Officer. In this ro |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2021 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File |
|
| October 8, 2021 |
Exhibit 99.1 ChemoCentryx Announces FDA Approval of TAVNEOSTM (avacopan) in ANCA-Associated Vasculitis ? First FDA-approved orally-administered inhibitor of the complement 5a receptor ? ? Company to hold conference call at 8:30 a.m. Eastern Time ? SAN CARLOS, Calif., OCTOBER 8, 2021 ? ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the U.S. Food and Drug Administration (FDA) has approved |
|
| October 8, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2021 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File |
|
| September 27, 2021 |
Exhibit 99.1 ChemoCentryx Announces Approval in Japan of TAVNEOSTM (Avacopan) for the Treatment of ANCA-Associated Vasculitis ? Approved for use in Japan in patients with microscopic polyangiitis and granulomatosis with polyangiitis ? SAN CARLOS, Calif., SEPTEMBER 27, 2021 ? ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Kissei Pharmaceutical Co., Ltd. has received approval from the Japa |
|
| September 27, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2021 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission F |
|
| August 10, 2021 |
As filed with the Securities and Exchange Commission on August 10, 2021 As filed with the Securities and Exchange Commission on August 10, 2021 Registration No. |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File |
|
| August 9, 2021 |
Exhibit 99.1 ChemoCentryx Reports Second Quarter 2021 Financial Results and Recent Highlights ? Company filed an amendment to its NDA for avacopan in the treatment of ANCA-associated vasculitis; PDUFA goal date extended to October 7, 2021? ? Applications for regulatory approval of avacopan in ANCA-associated vasculitis also under review by the European Medicines Agency and the Japan Pharmaceutical |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35420 ChemoCentryx, Inc. |
|
| July 6, 2021 |
Exhibit 99.1 ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis SAN CARLOS, Calif., July 6, 2021 ? ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that, following consultations with the U.S. Food and Drug Administration (FDA), it filed an amendment to its New Drug Application (NDA) fo |
|
| July 6, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2021 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 9, 2021 |
CCXI / ChemoCentryx Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* ChemoCentryx, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 16383L106 (CUSIP Number) May 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| May 24, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 7, 2021 |
Exhibit 99.1 ChemoCentryx Announces Results of FDA Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis SAN CARLOS, Calif., May 6, 2021 ? ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the outcome of the U.S. Food and Drug Administration (?FDA?) Arthritis Advisory Committee (?Committee?) on avacopan for the treatment of Antineutrophil Cytoplasmic Autoantibody (ANCA)-associated |
|
| May 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 3, 2021 |
Quarterly Report - 2021Q1 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35420 ChemoCentryx, Inc. |
|
| May 3, 2021 |
Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.1 CHEMOCENTRYX, INC. Non-Employee DIRECTOR COMPENSATION POLICY (As Amended and Restated Effective February 25, 2021) Non-employee members of the board of directors (the “Board”) of ChemoCentryx, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compensation de |
|
| April 29, 2021 |
Exhibit 99.1 ChemoCentryx Reports First Quarter 2021 Financial Results and Recent Highlights ? Applications for regulatory approval of avacopan in ANCA-associated vasculitis under review in the United States, Europe and Japan; PDUFA goal date of July 7, 2021, with Advisory Committee scheduled for May 6 ? ? Novel orally administered checkpoint inhibitor CCX559 featured at American Association for C |
|
| April 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File |
|
| April 7, 2021 |
Amended and Restated 2012 Employee Stock Purchase Plan Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 8, 2021 |
ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors EX-99.1 Exhibit 99.1 ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors MOUNTAIN VIEW, Calif., March 8, 2021 — ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company’s Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective March 2, 2021. “Susan Kanaya’s many fund |
|
| March 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 1, 2021 |
EX-10.34 4 ccxi-ex1034274.htm EX-10.34 Manufacturing and Supply Agreement Exhibit 10.34 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Manufacturing and Supply Agreement Manufacturing and Supply Agreement MANUFACTURING AND SUPPLY AGREEMENT THIS MANUFACTURING AND SUPPLY |
|
| March 1, 2021 |
Exhibit 10.13 December 23, 2020 Tausif ?Tosh? Butt Dear Tosh: On behalf of ChemoCentryx, Inc. (?ChemoCentryx? or the ?Company?), I am pleased to offer you employment as Executive Vice President, Chief Operating Officer. In this position, you will report to Thomas Schall, President and Chief Executive Officer, and will work from our office in Mountain View, California. Compensation & Benefits Your |
|
| March 1, 2021 |
Exhibit 99.1 ChemoCentryx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights ? The New England Journal of Medicine highlights results of ADVOCATE Phase III trial of avacopan in ANCA-associated vasculitis ? ? Applications for regulatory approval of avacopan in ANCA-associated vasculitis under review in the U.S. (PDUFA goal date of July 7, 2021), the E.U. (decision exp |
|
| March 1, 2021 |
Exhibit 99.1 ChemoCentryx Appoints Tausif (?Tosh?) Butt as Executive Vice President and Chief Operating Officer Brings more than two decades of executive management experience from global pharmaceutical companies MOUNTAIN VIEW, Calif., February 24, 2021 ? ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Tausif (?Tosh?) Butt as Executive Vice President and Chief Operating Offi |
|
| March 1, 2021 |
Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 1, 2021 |
EX-4.4 2 ccxi-ex4410.htm EX-4.4 Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ChemoCentryx, Inc. (we, us and our) has one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. Description of Common Stock General The following summary of the terms o |
|
| March 1, 2021 |
Subsidiaries of the Registrant. EX-21.1 5 ccxi-ex2118.htm EX-21.1 Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a list of subsidiaries of the Registrant as of December 31, 2020. Company Jurisdiction of Incorporation ChemoCentryx Limited United Kingdom ChemoCentryx Ireland Limited Ireland |
|
| March 1, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2021 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ChemoCentryx, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 16383L106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ChemoCentryx, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 16383L106 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 9) ChemoCentryx, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 16383L106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: ChemoCentryx Inc. Title of Class of Securities: Common Stock CUSIP Number: 16383L106 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* ChemoCentryx, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 16383L106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| December 21, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2020 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 21, 2020 |
EX-99.1 Exhibit 99.1 ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR) • As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment • The change from baseline to Week 26 |
|
| November 10, 2020 |
CCXI / ChemoCentryx, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ChemoCentryx Inc (Name of Issuer) Common Stock (Title of Class of Securities) 16383L106 (CUSIP Number) October 30, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| November 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 9, 2020 |
Exhibit 99.1 ChemoCentryx Reports Third Quarter 2020 Financial Results and Recent Highlights — New Drug Application (NDA) accepted for review by U.S. Food and Drug Administration (FDA) for avacopan in ANCA-associated vasculitis with PDUFA goal date of July 7, 2021 — — Marketing Authorization Application (MAA) validated by the European Medicines Agency (EMA) for avacopan in ANCA-associated vasculit |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35420 ChemoCentryx, Inc. |
|
| November 9, 2020 |
Lease Extension Letter, dated July 1, 2020, by and between Google Inc. and the Registrant. Exhibit 10.2 C O M M E R C I A L R E A L E S T A T E S E R V I C E S Sandy Izumi General Manager CBRE, Inc. Property Management 225 W. Santa Clara Street Suite 1200 San Jose, CA 95113 408 453 7483 Tel 408 437 3170 Fax 408 472 5104 Cell [email protected] www.cbre.com July 1, 2020 ChemoCentryx, Inc. 840-850 Maude Avenue Mountain View, CA 94043 Re:840-850 Maude Avenue – Two (2) Month Extension Dea |
|
| November 9, 2020 |
Exhibit 10.1 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. COMMERCIAL MANUFACTURING AGREEMENT (AVACOPAN) Between CHEMOCENTRYX, INC. and HOVIONE LLC THIS AGREEMENT (“Agreement”) is made and entered into as of August 17, 2020 (the “Effective Date”) by and between ChemoCe |
|
| November 4, 2020 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 28, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2020 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 28, 2020 |
EX-99.1 Exhibit 99.1 ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS) — Avacopan demonstrates statistically significant dose-dependent improvement in HiSCR (Hidradenitis Suppurativa Clinical Response) vs. placebo in pre-specified Hurley Stage III (severe HS) patients at 12 weeks; numerical improvement ob |
|
| September 1, 2020 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2020 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35420 ChemoCentryx, Inc. |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission |
|
| August 10, 2020 |
Master Manufacturing Services Agreement Exhibit 10.1 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Master Manufacturing Services Agreement March 18, 2020 Master Manufacturing Services Agreement Table of Contents ARTICLE 1 5 Structure of Agreement and Interpretation 5 1 |
|
| August 10, 2020 |
Exhibit 10.2 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. PRODUCT AGREEMENT (Includes Schedules A to D) PRODUCT AGREEMENT This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement dated March 18, 2020 between Patheon |
|
| August 10, 2020 |
EX-99.1 Exhibit 99.1 ChemoCentryx Reports Second Quarter 2020 Financial Results and Recent Highlights — U.S. New Drug Application (NDA) submitted for avacopan in ANCA-associated vasculitis — — Balance sheet bolstered with $325.7 million in net proceeds from June follow-on offering; total cash, cash equivalents and investments greater than $500 million at end of Q2 — — Topline data from AURORA tria |
|
| July 31, 2020 |
CCXI / ChemoCentryx, Inc. / Vifor (International) Ltd - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ChemoCentryx, Inc. (Name of Issuer) Common Stock, par value $0.001 Per Share (Title of Class of Securities) 16383L106 (CUSIP Number) Dr. Oliver P. Kronenberg Group General Counsel Vifor Pharma Management Ltd. Flughofstrasse 61, CH-8152, Glattbrugg, Switzerl |
|
| July 16, 2020 |
EX-99.12 Exhibit 99.12 10b5-1 SALE PLAN AGREEMENT June 26, 2020 This letter agreement (this “Letter Agreement”) confirms the terms and conditions under which Vifor (International) Ltd, an entity formed under the laws of Switzerland (the “Seller”), hereby establishes a plan (the “Plan”) to sell shares of common stock, par value $$0.001 (the “Securities”), of Chemocentryx, Inc. (the “Issuer”), and u |
|
| July 16, 2020 |
CCXI / ChemoCentryx, Inc. / Vifor (International) Ltd - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* ChemoCentryx, Inc. (Name of Issuer) Common Stock, par value $0.001 Per Share (Title of Class of Securities) 16383L106 (CUSIP Number) Dr. Oliver P. Kronenberg Group General Counsel Vifor Pharma Management Ltd. Flughofstrasse 61, CH-8152, Glattbru |
|
| June 11, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2020 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 11, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-239072 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1) Proposed maximum offering price per share Proposed maximum aggregate offering price Amount of registration fee(2) Common Stock, par value $0.001 per share 5,980,000 $58.00 $346,840,000 $45,020 (1) Includes |
|
| June 11, 2020 |
EX-1.1 Exhibit 1.1 CHEMOCENTRYX, INC. 5,200,000 Shares of Common Stock Underwriting Agreement June 10, 2020 SVB Leerink LLC Piper Sandler & Co. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o SVB Leerink LLC 255 California St, 12th Floor San Francisco, California 94111 c/o Piper Sandler & Co. 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: ChemoC |
|
| June 11, 2020 |
EX-99.2 Exhibit 99.2 June 10, 2020 ChemoCentryx Prices Public Offering of Common Stock MOUNTAIN VIEW, Calif., June 10, 2020 (GLOBE NEWSWIRE) — ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has priced an underwritten public offering of 5,200,000 shares of its common stock at a price to the public of $58.00 per share. The gross proceeds to ChemoCentryx from the offering, before underwriti |
|
| June 11, 2020 |
EX-99.1 Exhibit 99.1 June 10, 2020 ChemoCentryx Announces Proposed Public Offering of Common Stock MOUNTAIN VIEW, Calif., June 10, 2020 (GLOBE NEWSWIRE) — ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of its common stock. In connection with this offering, ChemoCentryx plans to grant the underwriters a 30-day option to purchase up to an addit |
|
| June 10, 2020 |
Subject to completion, dated June 10, 2020 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-239072 This prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but is not complete and may be changed. This prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting offers to buy these securities in any ju |
|
| June 10, 2020 |
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on June 10, 2020 Registration No. |
|
| June 10, 2020 |
EX-4.5 Exhibit 4.5 ChemoCentryx, Inc. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series. 5 Section 2.2. E |
|
| May 28, 2020 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2020 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 18, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2020 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 18, 2020 |
EX-99.1 Exhibit 99.1 ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS) MOUNTAIN VIEW, Calif. and ST GALLEN, CH, May 18, 2020 - ChemoCentryx, Inc., (NASDAQ: CCXI) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from a forty-six (46) patient Phase II dose-ranging trial in the orphan ki |
|
| May 14, 2020 |
Entry into a Material Definitive Agreement 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2020 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File |
|
| May 11, 2020 |
Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.3 CHEMOCENTRYX, INC. Non-Employee DIRECTOR COMPENSATION POLICY (As Amended and Restated Effective March 3, 2020) Non-employee members of the board of directors (the “Board”) of ChemoCentryx, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compensation descri |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35420 ChemoCentryx, Inc. |
|
| May 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 11, 2020 |
EXHIBIT 10.1 CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED amended and restated LOAN AND SECURITY AGREEMENT THIS AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT is made and dated as of January 8, 2020, and is entered into by and between CHEMOCENTRYX, INC., |
|
| May 11, 2020 |
EX-99.1 Exhibit 99.1 ChemoCentryx Reports First Quarter 2020 Financial Results and Recent Highlights - On track to file U.S. New Drug Application (NDA) for avacopan in ANCA-associated vasculitis mid-year - - Topline data from CCX140 LUMINA-1 Phase II clinical trial in Focal Segmental Glomerulosclerosis (FSGS) expected Q2 - - Completed enrollment of the AURORA clinical trial of avacopan in Hidraden |
|
| May 11, 2020 |
Exhibit 10.2 RIGHT TO INVEST AGREEMENT THIS RIGHT TO INVEST AGREEMENT (this “Agreement”) is made as of January 8, 2020, by and between ChemoCentryx, Inc., a Delaware corporation (“ChemoCentryx”) and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as a Lender (in such capacity, the “Lender”). RECITALS A.ChemoCentryx and Lender have entered into that certain Loan and Security Agreeme |
|
| April 6, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2020 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 6, 2020 |
DEF 14A 1 d897717ddef14a.htm DEFINITIVE PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, |
|
| April 6, 2020 |
The cure for anything is salt water — sweat, tears, or the sea EX-99.1 Exhibit 99.1 The cure for anything is salt water — sweat, tears, or the sea. So wrote Karen Blixen under the pen name of Isak Dinesen. While she couldn’t have known about ChemoCentryx (CCXI) during her lifetime, the aphorism could not be more apt than in its application to our story. In this letter I’ll describe the remarkable transformation of an enterprise; one where the alignment of toi |
|
| March 10, 2020 |
EX-99.1 Exhibit 99.1 ChemoCentryx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights — Announced positive topline data from pivotal Phase III ADVOCATE trial for ANCA-vasculitis in Q4; U.S. NDA filing expected mid-2020 — — “2020 4-Sight” on the horizon with topline data from four clinical trials expected in 2020: AURORA and ACCOLADE clinical trials of avacopan in Hidr |
|
| March 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2020 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission F |
|
| March 10, 2020 |
Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35420 ChemoCentryx, Inc. |
|
| March 10, 2020 |
EX-4.4 2 ccxi-ex44497.htm EX-4.4 Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ChemoCentryx, Inc. (we, us and our) has one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. Description of Common Stock General The following summary of the terms |
|
| March 10, 2020 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a list of subsidiaries of the Registrant as of December 31, 2019. Company Jurisdiction of Incorporation ChemoCentryx Limited United Kingdom ChemoCentryx Ireland Limited Ireland |
|
| March 6, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2020 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 14, 2020 |
CCXI / ChemoCentryx, Inc. / RA Capital Management, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ChemoCentryx, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 16383L106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 14, 2020 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 14, 2020 with respect to the shares of Common Stock of ChemoCentryx, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 11)1 ChemoCentryx, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 16383L106 (CUSIP Number) December 31, 2 |
|
| February 13, 2020 |
CCXI / ChemoCentryx, Inc. / Schall Thomas J. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 8) ChemoCentryx, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 16383L106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate |
|
| January 16, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2020 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission |
|
| January 16, 2020 |
EX-99.1 Exhibit 99.1 New Ideas. Better Medicines. Presentation to Investors January 2020Exhibit 99.1 New Ideas. Better Medicines. Presentation to Investors January 2020 Forward‐Looking Statements This presentation contains forward‐looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward‐looking statements by the following words: “may,” “will,” “c |
|
| January 10, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2020 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission |
|
| January 10, 2020 |
EX-99.1 EXHIBIT 99.1 ChemoCentryx Announces Credit Facility of Up to $100 Million with Hercules Capital — Non-dilutive funding vehicle strengthens balance sheet for registration filing of avacopan in ANCA vasculitis and anticipated approval and commercial launch — MOUNTAIN VIEW, Calif., January 9, 2020- ChemoCentryx, Inc., (NASDAQ: CCXI) today announced that the Company has secured a credit facili |
|
| January 10, 2020 |
CCXI / ChemoCentryx, Inc. / Cormorant Asset Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ChemoCentryx, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 16383L106 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| December 16, 2019 |
CCXI / ChemoCentryx, Inc. / Cormorant Asset Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ChemoCentryx, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 16383L106 (CUSIP Number) December 4, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| December 16, 2019 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of December 16, 2019, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file wit |
|
| November 25, 2019 |
EX-99.1 Exhibit 99.1 ChemoCentryx and VFMCRP Announce Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA-Associated Vasculitis — Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks — — Significantly reduced glucocorticoid |
|
| November 25, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2019 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commissio |
|
| November 4, 2019 |
Exhibit 10.1 LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made this 31st day of July, 2019, between ARE-SAN FRANCISCO NO. 63, LLC, a Delaware limited liability company (“Landlord”), and CHEMOCENTRYX, INC., a Delaware corporation (“Tenant”). Building: That certain to-be-constructed 6-story building to be known as 835 Industrial Road, San Carlos, California Premises: A portion of the Build |
|
| November 4, 2019 |
CCXI / ChemoCentryx, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35420 ChemoCentryx, Inc. |
|
| November 4, 2019 |
EX-99.1 Exhibit 99.1 ChemoCentryx Reports Third Quarter 2019 Financial Results and Recent Highlights — Topline data from pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA vasculitis expected mid-to-late fourth quarter — — Awarded $1 million grant from the U.S. Food and Drug Administration (FDA), to support the ACCOLADE Phase II trial of avacopan in C3 Glomerulopathy (C3G) |
|
| November 4, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2019 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission |
|
| August 5, 2019 |
EX-99.1 Exhibit 99.1 ChemoCentryx Reports Second Quarter 2019 Financial Results and Recent Highlights — Topline data from pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA Vasculitis on track for Q4 2019 — — Completed enrollment in LUMINA 1 Phase II trial of CCR2 inhibitor CCX140 in Focal Segmental Glomerulosclerosis (FSGS) — — Advancing three additional clinical trials; |
|
| August 5, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d788032d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2019 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorpo |
|
| August 5, 2019 |
CCXI / ChemoCentryx, Inc. 10-Q - Quarterly Report - 10-Q 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35420 ChemoCentryx, Inc. |
|
| August 5, 2019 |
Third Amendment to Lease, dated May 1, 2019, by and between Google Inc. and the Registrant. EX-10.1 Exhibit 10.1 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this “Amendment”) is made and entered into as of April 5, 2019 but effective as of May 1, 2019 (the “Effective Date”), by and between GOOGLE LLC, a Delaware limited liability company (“Landlord” or “Lessor”), and CHEMOCENTRYX, INC., a Delaware corporation (“Tenant” or “Lessee”). R E C I T A L S : A. Landlord and Tenant ar |
|
| August 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2019 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 28, 2019 |
Submission of Matters to a Vote of Security Holders 8-K 1 d753322d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2019 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorpora |
|
| May 15, 2019 |
CCXI / ChemoCentryx, Inc. CORRESP - - CORRESP 1 filename1.htm ChemoCentryx, Inc. 850 Maude Avenue Mountain View, CA 94043 May 15, 2019 VIA EDGAR Mr. Jeffrey Gabor Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E., Mail Stop 4546 Washington, D.C. 20549 Re: ChemoCentryx, Inc. Registration Statement on Form S-3 Filed May 7, 2019 File No. 333-231257 Dear Mr. Gabor: Pursuant to Rule 461 of Regulation C o |
|
| May 7, 2019 |
CCXI / ChemoCentryx, Inc. S-3 S-3 S-3 Table of Contents As filed with the Securities and Exchange Commission on May 7, 2019 Registration No. |
|
| May 7, 2019 |
EX-4.5 Exhibit 4.5 ChemoCentryx, Inc. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series. 5 Section 2.2. E |
|
| May 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2019 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File |
|
| May 6, 2019 |
EX-99.1 Exhibit 99.1 ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights — Succession of topline data readouts expected, starting with Pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA Vasculitis in Q4 2019 — — Conference call today at 5:00 p.m. Eastern Time — MOUNTAIN VIEW, Calif., May 6, 2019 — ChemoCentryx, Inc., (Nasdaq:CCXI), today announc |
|
| May 6, 2019 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35420 ChemoCentryx, Inc. |
|
| April 15, 2019 |
CCXI / ChemoCentryx, Inc. / Bio-techne Corp - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ChemoCentryx, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 16383L106 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| April 8, 2019 |
DEF 14A 1 d723961ddef14a.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Co |
|
| March 28, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2019 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commiss |
|
| March 28, 2019 |
ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors EX-99.1 Exhibit 99.1 ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors MOUNTAIN VIEW, Calif., March 28, 2019 — ChemoCentryx, Inc., (Nasdaq:CCXI), announced today that, effective March 27, 2019, Rita Jain, M.D., Senior Vice President and Chief Medical Officer of Akebia Therapeutics, has been appointed to the Company’s Board of Directors. Dr. Jain brings more than 20 years of drug developm |
|
| March 25, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2019 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission F |
|
| March 19, 2019 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CHEMOCENTRYX, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I – CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II – MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTI |
|
| March 19, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2019 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission F |
|
| March 11, 2019 |
Amended and Restated Bylaws of ChemoCentryx, Inc. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CHEMOCENTRYX, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I – CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II – MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES |
|
| March 11, 2019 |
Financial Statements and Exhibits 8-K/A 1 d721044d8ka.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2019 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of i |
|
| March 11, 2019 |
EX-99.1 Exhibit 99.1 ChemoCentryx Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights — Strong Progress Across Company’s Orphan Disease Franchise of Novel Renal and Dermal Therapeutics — — Pivotal top-line data expected from ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis, Q4 — — Launched AURORA clinical trial of avacopan in H |
|
| March 11, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2019 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commiss |
|
| March 11, 2019 |
Form 10-K Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35420 ChemoCentryx, Inc. |
|
| March 11, 2019 |
EX-10.34 Exhibit 10.34 AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT THIS AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT (the “First Amendment”) is dated as of December 13, 2018 (the “First Amendment Date”) and is entered into by and among CHEMOCENTRYX, INC., a Delaware corporation, the several banks and other financial institutions or entities from time to time parties hereto (collectively, refe |
|
| March 11, 2019 |
Subsidiaries of the Registrant. EX-21.1 Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a list of subsidiaries of the Registrant as of December 31, 2018. Company Jurisdiction of Incorporation ChemoCentryx Limited United Kingdom ChemoCentryx Ireland Limited Ireland |
|
| March 8, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2019 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 8, 2019 |
Amended and Restated Bylaws of ChemoCentryx, Inc. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CHEMOCENTRYX, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I – CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II – MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES |
|
| February 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 10)1 ChemoCentryx, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 16383L106 (CUSIP Number) February 12, 2 |
|
| February 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 9)1 ChemoCentryx, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 16383L106 (CUSIP Number) December 31, 20 |
|
| February 13, 2019 |
CCXI / ChemoCentryx, Inc. / Schall Thomas J. - AMENDMENT NO. 7 Passive Investment Amendment No. 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 7) ChemoCentryx, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 16383L106 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to de |
|
| January 30, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2019 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission |
|
| January 28, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2019 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commi |
|
| January 7, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2019 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission |
|
| December 4, 2018 |
EX-1.1 Exhibit 1.1 CHEMOCENTRYX, INC. EQUITY DISTRIBUTION AGREEMENT December 4, 2018 PIPER JAFFRAY & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), ChemoCentryx, Inc., a company organized under the laws of Delaware (the “Company”), proposes to issue and sell from time to time through Piper Jaff |
|
| December 4, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2018 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commi |
|
| December 4, 2018 |
Piper Jaffray The date of this prospectus supplement is December 4, 2018. 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-210731 Prospectus Supplement (To Prospectus dated April 28, 2016) $75,000,000 Common stock We have entered into an equity distribution agreement with Piper Jaffray & Co. relating to shares of our common stock offered by this prospectus supplement. In accordance with the terms of the equity distribution agreement, we may |
|
| November 8, 2018 |
EX-99.1 Exhibit 99.1 ChemoCentryx Reports Third Quarter 2018 Financial Results and Recent Highlights — Large, controlled clinical trial of avacopan in Hidradenitis Suppurativa (HS) on track to launch in late 2018 – — $186 million in cash and investments at September 30, 2018 — — Received Orphan Drug Designation for CCX140 in Focal Segmental Glomerulosclerosis (FSGS) — — Conference call today at 5: |
|
| November 8, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2018 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commi |
|
| November 8, 2018 |
CCXI / ChemoCentryx, Inc. 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35420 ChemoCentryx, Inc. |
|
| November 2, 2018 |
EX-99.3 Exhibit 99.3 Execution Version AGREEMENT This Agreement (this “Agreement”) is made and entered into as of September 17, 2018, by and among the persons and entities listed on Schedule A hereto (each, individually, a “Vifor Entity” and collectively, the “Vifor Entities”) and ChemoCentryx, Inc., a Delaware corporation (the “Company”). WHEREAS, the Vifor Entities and their respective affiliate |
|
| November 2, 2018 |
EX-99.2 Exhibit 99.2 EXECUTION VERSION STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this Agreement) is made as of September 17, 2018, by and between Glaxo Group Limited, a limited company organized under the laws of England and Wales, with registered seat at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom (Seller), and Vifor (International) Ltd., a limited company |
|
| November 2, 2018 |
CCXI / ChemoCentryx, Inc. / Vifor (International) Ltd - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* ChemoCentryx, Inc. (Name of Issuer) Common Stock, par value $0.001 Per Share (Title of Class of Securities) 16383L106 (CUSIP Number) Dr. Oliver P. Kronenberg Group General Counsel Vifor Pharma Management Ltd. Flughofstrasse 61, CH-8152, Glattbrugg, Switzerland + |
|
| November 2, 2018 |
EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of November 1, 2018, is made by and between Vifor (International) Ltd., an entity formed under the laws of Switzerland, Vifor Pharma Ltd., an entity formed under the laws of Switzerland, and Vifor Fresenius Medical Care Renal Pharma Ltd., an entity formed under the laws of Switzerland. The foregoing are collectively |
|
| October 18, 2018 |
CCXI / ChemoCentryx, Inc. / GLAXOSMITHKLINE PLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* CHEMOCENTRYX, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 16383L106 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 (Name, Address and Tele |
|
| September 26, 2018 |
ChemoCentryx, Inc. 850 Maude Avenue Mountain View, CA 94043 Attn: Corporate Secretary (650) 210-2900 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-210731 This prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but is not complete and may be changed. This prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting offers to buy these securities in any ju |
|
| September 18, 2018 |
CCXI / ChemoCentryx, Inc. / GLAXOSMITHKLINE PLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* CHEMOCENTRYX, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 16383L106 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 (Name, Address and Tele |
|
| September 18, 2018 |
STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of September 17, 2018, by and between Glaxo Group Limited, a limited company organized under the laws of England and Wales, with registered seat at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom (“Seller”), and Vifor (International) Ltd. |
|
| August 9, 2018 |
EX-99.1 Exhibit 99.1 ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights — Completed patient enrollment in Phase III ADVOCATE trial of avacopan in ANCA-associated vasculitis — — Ongoing clinical trials with avacopan in C3 Glomerulopathy (C3G) and CCX140 in Focal Segmental Glomerulosclerosis (FSGS), diseases with no approved therapies – — Launch of clinical development |
|
| August 9, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2018 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission F |
|
| August 9, 2018 |
EX-10.1 Exhibit 10.1 June 6, 2018 Vifor (International) Ltd. Rechenstrasse 37 CH-9014 St. Gallen Switzerland Re: Grant of Rights to CCX168 in China Ladies and Gentlemen: As you know, Vifor Fresenius Medical Care Renal Pharma Ltd. (“VFMCRP”) and ChemoCentryx, Inc. (“ChemoCentryx”) are parties to that certain Collaboration and License Agreement, dated May 9, 2016, amended May 22, 2017 (the “VFMCRP A |
|
| August 9, 2018 |
CCXI / ChemoCentryx, Inc. 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35420 ChemoCentryx, Inc. |
|
| August 9, 2018 |
EX-10.2 Exhibit 10.2 June 6, 2018 Vifor (International) Ltd. Rechenstrasse 37 CH-9014 St. Gallen Switzerland Re: Grant of Rights to CCX140 in China Ladies and Gentlemen: As you know, Vifor Fresenius Medical Care Renal Pharma Ltd. (“VFMCRP”) and ChemoCentryx, Inc. (“ChemoCentryx”) are parties to that certain Collaboration and License Agreement, dated December 22, 2016 (the “VFMCRP Agreement”), purs |
|
| August 9, 2018 |
EX-10.3 Exhibit 10.3 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT (the “Amendment”) is effective as of June 6, 2018 |
|
| June 7, 2018 |
Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2018 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commissio |
|
| May 24, 2018 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2018 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commissio |
|
| May 9, 2018 |
EX-99.1 2 d581732dex991.htm EX-99.1 Exhibit 99.1 ChemoCentryx Reports First Quarter 2018 Financial Results and Recent Highlights — Patient enrollment in Phase III ADVOCATE trial of avacopan in the treatment of ANCA-associated vasculitis exceeds 85%; Conditional Marketing Authorization (CMA) application under review with European Medicines Agency (EMA) — — Ongoing clinical trials with avacopan in C |
|
| May 9, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d581732d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2018 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incor |
|
| May 9, 2018 |
Amended and Restated Non-Employee Director Compensation Policy. EX-10.1 2 d562464dex101.htm EX-10.1 Exhibit 10.1 CHEMOCENTRYX, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (As Amended and Restated Effective March 6, 2018) Non-employee members of the board of directors (the “Board”) of ChemoCentryx, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Policy (this “Policy”). The |
|
| May 9, 2018 |
CCXI / ChemoCentryx, Inc. FORM 10-Q (Quarterly Report) Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35420 ChemoCentryx, Inc. |
|
| April 6, 2018 |
CCXI / ChemoCentryx, Inc. DEFINITIVE PROXY STATEMENT DEF 14A 1 d488872ddef14a.htm DEFINITIVE PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, |
|
| March 12, 2018 |
Employment Agreement, effective as of May 2, 2016, by and between the Registrant and Rajinder Singh. EX-10.13 Exhibit 10.13 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made effective as of May 2, 2016 (“Effective Date”), by and between ChemoCentryx, Inc., a Delaware corporation (the “Company”), and Rajinder Singh, D.Phil. (“Executive”). WHEREAS, the Company desires to employ Executive and Executive desires to commence employment with the Company on the terms and conditions set |
|
| March 12, 2018 |
EX-10.14 Exhibit 10.14 October 11, 2016 Dr. Jan Hillson **** **** Dear Jan: It is with great pleasure that I offer you employment at ChemoCentryx, Inc. (“ChemoCentryx” or the “Company”), on the terms set forth below. As you know, ChemoCentryx is a research-driven drug discovery and development company that is committed to the creation of novel therapeutics for inflammatory diseases and cancer, bas |
|
| March 12, 2018 |
CCXI / ChemoCentryx, Inc. FORM 10-K (Annual Report) Form 10-K Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35420 ChemoCentryx, Inc. |
|
| March 12, 2018 |
Subsidiaries of the Registrant. EX-21.1 Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a list of subsidiaries of the Registrant as of December 31, 2017. Company Jurisdiction of Incorporation ChemoCentryx Limited United Kingdom |
|
| March 9, 2018 |
8-K 1 d546215d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2018 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of inc |
|
| March 9, 2018 |
Exhibit 99.1 Exhibit 99.1 ChemoCentryx Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights — Phase III ADVOCATE trial of avacopan in treatment of ANCA vasculitis nears 75% of patient enrollment target as European Medicine Agency continues review process of Conditional Marketing Authorization application — — Strengthened balance sheet with up to $100 million in new cap |
|
| March 9, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2018 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commissi |
|
| February 14, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 8)1 ChemoCentryx, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 16383L106 (CUSIP Number) December 31, 20 |
|
| February 13, 2018 |
CCXI / ChemoCentryx, Inc. / Schall Thomas J. - AMENDMENT NO. 6 Passive Investment Amendment No. 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 6) ChemoCentryx, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 16383L106 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to de |
|
| January 8, 2018 |
CCXI / ChemoCentryx, Inc. FORM 8-K (Current Report) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2018 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commis |
|
| January 8, 2018 |
Employment Agreement, dated January 3, 2018, by and between ChemoCentryx, Inc. and William Fairey. EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made effective as of January 3rd, 2018 (?Effective Date?), by and between ChemoCentryx, Inc., a Delaware corporation (the ?Company?), and Bill Fairey (?Executive?). WHEREAS, the Company desires to employ Executive and Executive desires to commence employment with the Company on the terms and conditions set forth b |
|
| January 8, 2018 |
EX-99.1 Exhibit 99.1 ChemoCentryx Strengthens Senior Executive Team with the Appointment of William Fairey as Executive Vice President and Chief Operating Officer MOUNTAIN VIEW, Calif., January 8, 2018 (GLOBE NEWSWIRE) ? ChemoCentryx, Inc., (Nasdaq: CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced the appoint |
|
| January 4, 2018 |
EX-99.1 Exhibit 99.1 ChemoCentryx Secures up to $100 Million in New Capital Commitments ? ChemoCentryx to Receive $50 Million Milestone from Vifor Pharma for Validation of Conditional Marketing Authorization Application for Avacopan for the Treatment of ANCA Vasculitis ? ? Company Also Enters into $50 Million Growth Capital Financing Agreement with Hercules Capital ? MOUNTAIN VIEW, Calif., January |
|
| January 4, 2018 |
EX-10.1 Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of December 28, 2017 and is entered into by and between CHEMOCENTRYX, INC., a Delaware corporation, and each of its Qualified Subsidiaries (hereinafter collectively referred to as the ?Borrower?), the several banks and other financial institutions or entities from time to time parties to this Agr |
|
| January 4, 2018 |
CCXI / ChemoCentryx, Inc. FORM 8-K (Current Report) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2017 ChemoCentryx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Comm |
|
| November 7, 2017 |
EX-99.1 Exhibit 99.1 ChemoCentryx Reports Third Quarter 2017 Financial Results and Recent Highlights ? Phase III ADVOCATE trial of avacopan remains on track to complete enrollment in mid-2018 ? ? Patient enrollment ongoing in registration-supporting trial for avacopan in the treatment C3 Glomerulopathy (C3G) ? ? Plan to launch registration-supporting trial for CCX140 in the treatment of Focal Segm |
|
| November 7, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2017 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission |
|
| November 7, 2017 |
CCXI / ChemoCentryx, Inc. FORM 10-Q (Quarterly Report) Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 8, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d439107d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2017 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of in |
|
| August 8, 2017 |
EX-99.1 Exhibit 99.1 ChemoCentryx Reports Second Quarter 2017 Financial Results and Recent Highlights ? Pivotal Phase III ADVOCATE trial of avacopan on track to complete enrollment in mid-2018 as projected ? ? Launching second trial of avacopan in patients with C3 Glomerulopathy (C3G) ? ? Conference call today at 5:00 p.m. Eastern Time ? MOUNTAIN VIEW, Calif., August 8, 2017 ? ChemoCentryx, Inc., |
|
| August 8, 2017 |
EX-10.1 Exhibit 10.1 CERTAIN MATERIAL (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT (the “Amendment”) is effective as of May 22, 2017 (t |
|
| August 8, 2017 |
CCXI / ChemoCentryx, Inc. FORM 10-Q (Quarterly Report) Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35420 ChemoCentry |
|
| August 8, 2017 |
Second Amendment to Lease, dated April 13, 2017, by and between Google Inc. and the Registrant. EX-10.2 Exhibit 10.2 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this “Amendment”) is made and entered into effective as of April 13, 2017 (the “Effective Date”), by and between GOOGLE INC., a Delaware corporation (“Landlord” or “Lessor”), and CHEMOCENTRYX, INC., a Delaware corporation (“Tenant” or “Lessee”). R E C I T A L S : A. Landlord and Tenant are parties to that certain Lease |
|
| August 2, 2017 |
ChemoCentryx FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2017 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commissi |
|
| May 25, 2017 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2017 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 10, 2017 |
ChemoCentryx FORM 10-Q (Quarterly Report) Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 10, 2017 |
Letter Agreement dated as of February 13, 2017 between the Registrant and Vifor (International) Ltd. EX-10.1 Exhibit 10.1 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. February 13, 2017 Vifor (International) Ltd. Rechenstrasse 37 CH-9014 St. Gallen Switzerland Re: Grant of Rights to CCX168 in Expanded Territory Ladies and G |
|
| May 10, 2017 |
Non-Employee Director Compensation Policy. EX-10.2 Exhibit 10.2 CHEMOCENTRYX, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (As Amended and Restated Effective March 1, 2017) Non-employee members of the board of directors (the ?Board?) of ChemoCentryx, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Policy (this ?Policy?). The cash and equity compensatio |
|
| May 10, 2017 |
EX-99.1 Exhibit 99.1 ChemoCentryx Reports First Quarter 2017 Financial Results ? Phase III clinical trial of avacopan for the treatment of ANCA Vasculitis underway as Journal of American Society of Nephrology (JASN) publishes results of successful Phase II CLEAR clinical trial ? ? Received FDA Orphan Drug Designation for avacopan in the treatment of C3 Glomerulopathy (C3G) ? ? Conference call toda |
|
| May 10, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2017 CHEMOCENTRYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-35420 94-3254365 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 10, 2017 |
ChemoCentryx DEFINITIVE PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 14, 2017 |
ChemoCentryx FORM 10-K (Annual Report) Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35420 ChemoCentryx, Inc. |
|
| March 14, 2017 |
EX-99.1 Exhibit 99.1 ChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial Results ? Expanded Vifor Pharma partnership now totals $155 million in upfront cash commitments, $1.2 billion in potential milestone payments, plus substantial royalties on potential net sales ? ? Initiated Phase III clinical trial of Avacopan for the treatment of ANCA Vasculitis ? ? Conference call today at 5:00 |
